Ferrous Bisglycinate for Health & Longevity
Evidence Review created on 11/07/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: Ferrous Bisglycinate Chelate, Iron Bisglycinate, Iron Bisglycinate Chelate, Iron Bis-Glycine Chelate, Ferrous Glycinate, Iron Glycinate, Ferrochel
Motivation
Ferrous bisglycinate (iron bisglycinate) is a form of supplemental iron in which each iron atom is bound to two molecules of glycine, the simplest amino acid. Iron is needed to make the protein in red blood cells that carries oxygen and to run the energy machinery inside cells, and low iron is one of the most common nutrient shortfalls worldwide. This form is marketed as easier on the stomach and better absorbed than the cheaper standard iron supplements long used in medicine.
It is widely sold as a supplement and is popular with menstruating women, regular blood donors, endurance athletes and people eating plant-based diets. Interest has grown because many people stop taking standard iron supplements because of digestive side effects, and because iron is a double-edged nutrient: too little causes tiredness and anemia, while too much builds up in the body with no natural way out.
This review examines what the human evidence shows about ferrous bisglycinate for health and longevity: who benefits, how it compares with other iron forms, what risks it carries, and how it is dosed and monitored.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
Overview articles and a narrative review on ferrous bisglycinate, on oral iron supplementation and on iron excess more broadly.
-
Iron amino acid chelates - Hertrampf & Olivares, 2004
A University of Chile narrative review of how ferrous bisglycinate is absorbed, how food components and body iron stores regulate its uptake, and where trial evidence against iron salts remains thin.
-
Does low iron intake change exercise capacity? - Peter Attia
Covers iron repletion, the therapeutic category ferrous bisglycinate belongs to: how low ferritin (the body’s iron-storage protein) impairs exercise before anemia, confirming deficiency before supplementing, and when oral versus intravenous iron fits.
-
Excess Iron and Brain Degeneration: The Little-Known Link - Kathleen Anderson
Argues against supplemental iron unless deficiency is documented, citing age-related iron accumulation and its links to neurodegeneration, the same excess-iron mechanism relevant to unneeded ferrous bisglycinate use.
Only three items are listed because no further directly relevant overview content qualified. No dedicated content on iron supplementation was found from Chris Kresser (his iron post, Iron Behaving Badly: The Role of Iron Overload in Metabolic Disease, introduces a talk on iron overload in metabolic disease, not supplementation), Andrew Huberman (only a short “Iron Load & Aging” segment within the guest episode Dr. David Sinclair: The Biology of Slowing & Reversing Aging) or Lifespan.io (its iron-related article, Vitamin C Alleviates Aging in Cynomolgus Monkeys, concerns vitamin C and age-related iron accumulation, not iron supplementation), and Rhonda Patrick’s freely available iron content is limited to a segment on iron overload in worms within the guest episode Gordon Lithgow, Ph.D. on Protein Aggregation, Iron Overload & the Search for Longevity Compounds and short clips.
Grokipedia
-
An AI-written encyclopedia entry on the compound’s chemistry, absorption and tolerability; notably it acknowledges trials where higher-dose ferrous sulfate outperformed lower-dose bisglycinate for raising iron stores.
Examine
-
Examine’s evidence summary for iron as a nutrient, covering deficiency, dosing, absorption and side effects; Examine has no separate page for the bisglycinate form.
ConsumerLab
-
Iron Supplements Review (Iron Pills, Liquids and Chews)
Independent laboratory testing of iron supplements, including bisglycinate products, with a section comparing iron forms; full test results and top picks are restricted to members.
Systematic Reviews
Systematic reviews and meta-analyses (studies that pool the results of many trials) on ferrous bisglycinate and hemoglobin (the oxygen-carrying protein of red blood cells), and on oral iron in general where none covers the bisglycinate form.
-
The effects of oral ferrous bisglycinate supplementation on hemoglobin and ferritin concentrations in adults and children: a systematic review and meta-analysis of randomized controlled trials. - Fischer et al., 2023
The only meta-analysis dedicated to ferrous bisglycinate (17 randomized trials): higher hemoglobin and fewer gastrointestinal events in pregnancy; pooled data include two since-retracted trials.
-
Comparative Effectiveness of Iron Supplementation in Indian Pregnant Women: A Network Meta-Analysis of Randomized Controlled Trials. - Joshi et al., 2026
A network meta-analysis (ranks many treatments together) of 17 Indian pregnancy trials; ferrous bisglycinate ranked above ferrous sulfate for hemoglobin, behind ferrous asparto glycinate.
-
Daily iron supplementation for improving anaemia, iron status and health in menstruating women. - Low et al., 2016
About iron in general, not bisglycinate: 67 trials in menstruating women show less anemia and fatigue, better exercise performance, and more gastrointestinal side effects.
-
Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. - Tolkien et al., 2015
About ferrous sulfate, the usual comparator: 43 trials; in the 20 placebo-controlled ones, gastrointestinal side-effect odds more than doubled, the harm bisglycinate aims to reduce.
-
Iron supplementation benefits physical performance in women of reproductive age: a systematic review and meta-analysis. - Pasricha et al., 2014
About iron in general, mostly salts: 24 trials in women of reproductive age show improved maximal and submaximal exercise performance.
No systematic review addresses iron accumulation or other long-term risks of ferrous bisglycinate; the principal long-term risk is therefore unrepresented here.
Mechanism of Action
Ferrous bisglycinate is one ferrous (Fe²⁺) iron atom held in a ring-shaped chelate (a metal gripped by two bonds from the same molecule) by two glycine molecules. The chelate stays soluble at intestinal pH and partly shields iron from phytates (plant phosphate compounds) and polyphenols (plant compounds in tea, coffee and wine), although tea and espresso still halved its absorption in one study (Layrisse 2000).
- Absorption pathway: Released iron enters gut-lining cells through DMT1 (divalent metal transporter 1, the main iron-uptake channel). Competing views exist: iron from the chelate competed with ferrous sulfate for this pathway (Pizarro 2002), yet in maize meals it did not exchange with food iron, implying partial protection (Bovell-Benjamin 2000).
- Regulation: Hepcidin (a liver hormone that blocks the iron exporter ferroportin) rises as stores fill; consistently, absorption from the chelate fell as ferritin rose (Bovell-Benjamin 2000).
- Use in the body: Absorbed iron binds transferrin (the blood’s iron carrier) and is built into hemoglobin, myoglobin (the muscle oxygen store) and mitochondrial enzymes.
- Pharmacology: No single half-life applies; serum iron peaks within hours, but body iron persists for years because humans lack an excretion route. Distribution follows normal iron: bone marrow, liver, spleen and muscle. It has no receptor selectivity, and no cytochrome P450 (liver drug-metabolizing enzyme) metabolism is involved; glycine joins the amino acid pool.
- Harm pathway: Unabsorbed iron in the colon can irritate the gut, and excess free iron drives Fenton chemistry (iron-catalyzed formation of damaging hydroxyl radicals).
Historical Context & Evolution
Amino acid chelates of minerals were developed commercially by Albion Laboratories (Utah, now part of Balchem), which markets ferrous bisglycinate as Ferrochel. Its original intended use was food fortification and treatment of iron-deficiency anemia; the U.S. FDA (Food and Drug Administration) raised no questions about Albion’s 1999 notice declaring it safe for fortifying foods (FDA GRN 19).
- Early findings: Isotope studies (tracking labeled iron atoms) found four times higher absorption than ferrous sulfate from fortified maize porridge (Bovell-Benjamin 2000) and about twice from fortified bread breakfasts (Layrisse 2000). An early pediatric trial was co-authored by Albion staff, a direct financial interest (Pineda 2001).
- Clinical expansion: Trials followed in pregnancy, one partly funded by supplement firms Pharmovital and Vitalkost (Milman 2014), patients after cancer surgery (Ferrari 2012) and blood donors, the last run by the Dutch blood service Sanquin, which has an operational interest in donor retention (Karregat 2025).
- Path to health optimization: Interest grew among health-focused adults because many stop iron salts because of gastrointestinal discomfort, and because low iron without anemia was linked to fatigue and reduced exercise capacity.
- What changed: Later trials qualified the early enthusiasm. A low 18 mg dose fell short of 60 mg ferrous sulfate in raising stores (Fischer 2023), and two Egyptian pregnancy trials favoring bisglycinate were retracted in 2026 (Abdel Moety 2017, Abbas 2019). Tolerability advantages and efficacy at lower doses remain supported by other trials, some independently funded.
Expected Benefits
High 🟩 🟩 🟩
Correction and Prevention of Iron Deficiency and Anemia
Ferrous bisglycinate supplies absorbable iron for hemoglobin synthesis and refills ferritin stores in people who are iron deficient. Independent groups support this: Karregat’s placebo-controlled trial in 830 Dutch blood donors aged 18–80 showed less iron deficiency (Karregat 2025), and active-comparator trials by Milman (Denmark) and Ferrari (Italy) matched iron salts at lower doses (Milman 2014, Ferrari 2012). Gains are small when stores are already adequate: mostly iron-replete Cambodian women reached ferritin of 84 versus 78 µg/L on placebo (Fischer 2023).
Magnitude: In donors with ferritin at or below 30 µg/L, iron deficiency at 56 days affected 1% on 60 mg daily versus 51% on daily placebo, reported odds ratio (OR, the odds of the outcome in one group relative to the other) 0.60 (95% confidence interval [CI, the range likely to contain the true value] 0.55–0.66) (Karregat 2025).
Medium 🟩 🟩
Better Gastrointestinal Tolerability Than Iron Salts ⚠️ Conflicted
Trials report fewer nausea, constipation and abdominal-pain complaints with ferrous bisglycinate than with iron salts, attributed to less unabsorbed iron reaching the colon. Most compared a lower bisglycinate dose with a higher salt dose, as in Milman’s 25 versus 50 mg trial, partly funded by supplement firms Vitalkost and Pharmovital (Milman 2024). At equal 50 mg doses, Coplin’s crossover trial in 38 women found no statistically significant difference (Coplin 1991). Net reading: the advantage is consistent at the lower doses bisglycinate permits, but unproven at equal doses.
Magnitude: Pooled incidence rate ratio (IRR, the ratio of event rates between groups) 0.36 (95% CI 0.17–0.76) versus other oral iron in pregnant women, equal to 255 fewer per 1,000 women (331 to 96 fewer), a pool that includes two since-retracted trials (Fischer 2023).
Low 🟩
Reduced Fatigue in Iron-Deficient Non-Anemic Women ⚠️ Conflicted
In fatigued menstruating women with ferritin below 50 µg/L, ferrous sulfate reduced fatigue (Vaucher 2012), indirect in compound. In low-ferritin donors, bisglycinate did not change fatigue versus placebo (Karregat 2025). Net reading: benefit appears confined to already-fatigued women.
Magnitude: Fatigue scores fell 47.7% with iron versus 28.8% with placebo, a difference of −18.9% (95% CI −34.5 to −3.2) (Vaucher 2012).
Improved Exercise Capacity in Iron-Deficient Women
Iron supplementation raised peak aerobic capacity and lowered heart rate at set workloads in women of reproductive age (Pasricha 2014). Trials used mostly iron salts, not bisglycinate, so the evidence is indirect in compound.
Magnitude: Relative VO2 max (maximal oxygen uptake) 2.35 mL/kg/min higher than control (95% CI 0.82–3.88; 18 studies) (Pasricha 2014).
Relief of Restless Legs Symptoms
In restless legs syndrome (an urge to move the legs, worse at rest and at night), iron reduced symptom severity versus placebo (Trotti 2019). Trials used intravenous and oral iron salts, not bisglycinate, so the evidence is indirect in compound and route.
Magnitude: International Restless Legs Scale score (0–40) 3.78 points lower than placebo (95% CI 1.31 to 6.25 lower; 7 trials) (Trotti 2019).
Improved Attention and Concentration
In randomized trials of children over six, adolescents and women, oral iron improved attention and concentration regardless of iron status, and IQ (intelligence quotient) in anemic participants (Falkingham 2010). Trials were small, short and did not test bisglycinate, so the evidence is indirect in compound.
Magnitude: Attention and concentration improved by a standardized mean difference (SMD, the effect in standard-deviation units) of 0.59 versus control (95% CI 0.29 to 0.90) (Falkingham 2010); IQ was 2.5 points higher in anemic groups (95% CI 1.24 to 3.76) (Falkingham 2010).
Speculative 🟨
Healthspan or Lifespan Extension in Iron-Replete Adults
No human study has tested this. Iron supports mitochondrial energy enzymes, but genetic data link higher iron status to shorter lifespan (Daghlas 2021); benefit beyond correcting deficiency is mechanistic speculation only.
Benefit-Modifying Factors
- Genetic polymorphisms: Variants in TMPRSS6 (a gene encoding matriptase-2, which restrains hepcidin) cause iron-refractory iron-deficiency anemia with poor response to any oral iron (Heeney 2014). Thalassemia trait (inherited small red cells) mimics iron deficiency but does not respond.
- Baseline ferritin: Absorption from bisglycinate rises as ferritin falls (Bovell-Benjamin 2000); iron-replete users gain little (Fischer 2023).
- Sex: Menstruating women, with higher iron losses, are the main beneficiaries; in men and postmenopausal women, deficiency often signals underlying disease that iron alone does not address, per gastroenterologists who perform the endoscopies (camera examinations of the gut) they advise (Snook 2021).
- Gastric surgery and acid suppression: After gastrectomy (stomach removal), ferrous sulfate outperformed bisglycinate (Mimura 2008); long-term acid-suppressing medications were linked to iron deficiency (Lam 2017).
- Heart failure and chronic inflammation: High-dose oral iron did not improve exercise capacity in iron-deficient heart failure (Lewis 2017); inflammation raises hepcidin, blunting oral absorption.
- Age: Older adults respond: Ferrari’s 45–75-year-old patients corrected mild anemia on 14–28 mg daily (Ferrari 2012). Reduced stomach acid with age may lower absorption.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: bisglycinate-specific harm data come from active-comparator trials and two placebo-controlled trials (in Dutch blood donors and Cambodian women), overload data come from a single case report or genetic iron loading, and poisoning data from other iron forms.
Medium 🟥 🟥
No risk reaches Medium: the placebo-controlled bisglycinate trials found no overall excess of gastrointestinal discomfort, only a small constipation-score rise on 60 mg daily (Karregat 2025), and no gut inflammation (Fischer 2023), and the remaining harm data are uncontrolled, indirect (other iron forms, genetic iron loading) or biomarker-only.
Low 🟥
Gastrointestinal Adverse Events ⚠️ Conflicted
Nausea, constipation and abdominal pain arise as unabsorbed iron irritates the gut; ferrous sulfate’s excess over placebo is established (Tolkien 2015). In placebo-controlled FORTE, bisglycinate caused no overall excess, only higher constipation scores on 60 mg daily (Karregat 2025). Net reading: little excess beyond constipation at 60 mg daily.
Magnitude: Gastrointestinal side effects in 6.7% (60 mg once daily) and 9.9% (60 mg twice daily) versus 11.1% with 100 mg ferrous ascorbate over 8 weeks, no between-group test reported, in GlaxoSmithKline’s sponsor-run registration trial of a tablet also containing folic acid, vitamin B12 and zinc (NCT01160198).
Iron Accumulation in Iron-Replete Users and Hemochromatosis Carriers
Humans cannot excrete excess iron; unneeded supplementing builds stores, especially in HFE C282Y homozygotes (two copies of a variant in HFE, a hepcidin-regulating gene; causes hereditary hemochromatosis, inherited iron overload). A case report tied long-term bisglycinate use to organ overload (Sugimori 2025); other data are genetic, hence indirect (Pilling 2019).
Magnitude: Over seven years, 15.7% of C282Y-homozygous men developed an associated condition (liver disease, arthritis, diabetes) versus 5.0% of men without the variant (Pilling 2019).
Delayed Diagnosis of the Cause of Iron Deficiency
Self-treatment can normalize blood counts while a bleeding source, including colorectal cancer, goes unexamined. British Society of Gastroenterology guidance reports underlying disease in about a third of affected men and postmenopausal women; its gastroenterologist members earn revenue from the endoscopies it recommends (Snook 2021).
Magnitude: About one-third of men and postmenopausal women presenting with iron-deficiency anemia have an underlying pathology, mostly gastrointestinal (no control group) (Snook 2021).
Accidental Iron Poisoning in Young Children
Iron overdose is a leading cause of fatal poisoning in children under six, and the FDA requires a warning on iron-containing supplements in tablet or capsule form (21 CFR 101.17). Data come from iron products generally, not bisglycinate specifically (Tenenbein 2005).
Magnitude: U.S. iron-poisoning deaths in children under six fell from 29 in the 10 years before unit-dose packaging rules to 1 in the 5 years after (no control group) (Tenenbein 2005).
Speculative 🟨
Gut Microbiome Shift Toward Potentially Pathogenic Bacteria
Ferrous bisglycinate increased Enterobacteriaceae (a family including Escherichia coli and Salmonella) (Finlayson-Trick 2023); calprotectin (a gut-inflammation marker) was unchanged (Fischer 2023). Clinical relevance is unestablished.
Risk-Modifying Factors
- Genetic polymorphisms: HFE C282Y homozygosity (about 1 in 156 people of European descent) sharply raises overload risk (Pilling 2019); C282Y/H63D compound heterozygotes (one copy of each variant) carry a modest excess (Pilling 2019).
- Baseline iron status: High transferrin saturation (the share of the blood’s iron carrier loaded with iron) or ferritin before starting signals overload risk; EASL (European Association for the Study of the Liver) thresholds, revenue-neutral for its members, guide evaluation (EASL 2022).
- Sex: Men accumulate iron earlier; women are partly protected until menopause (Pilling 2019).
- Pre-existing conditions: Chronic liver disease, transfusion-dependent anemias and hemochromatosis raise overload harm; inflammatory bowel disease may worsen with gut iron exposure; constipation-prone people tolerate iron less well.
- Age: Older men and postmenopausal women more often have gastrointestinal disease, including cancer, behind iron deficiency, per guidance whose gastroenterologist authors perform the endoscopies it advises (Snook 2021), and more constipation from concurrent medications.
Key Interactions & Contraindications
Documented interactions:
- Levothyroxine: Iron binds thyroid hormone in the gut; co-ingested ferrous sulfate raised TSH (thyroid-stimulating hormone) from 1.6 to 5.4 mU/L with hypothyroid symptoms (Campbell 1992). Separating doses by at least 4 hours avoids it.
- Levodopa/carbidopa (Sinemet): Ferrous sulfate cut levodopa absorption by 30% (Campbell 1990) and carbidopa by over 75% (Campbell 1990), risking poorer Parkinson symptom control. Separating doses by at least 2 hours avoids it.
- Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin): Ferrous sulfate reduced ciprofloxacin blood levels to about a third, risking treatment failure (Polk 1989). Taking the antibiotic 2 hours before or 6 hours after iron avoids it.
- Tetracycline antibiotics (doxycycline, tetracycline): Ferrous sulfate taken together seriously impaired tetracycline and doxycycline absorption, risking treatment failure (Neuvonen 1970). Separating doses by at least 2–3 hours avoids it.
- Acid suppressants, prescription and over-the-counter (omeprazole, pantoprazole; famotidine): Two or more years of proton pump inhibitors (potent stomach-acid suppressants) were linked to iron deficiency, reducing iron absorption (Lam 2017). Ferritin monitoring detects the shortfall.
- Calcium supplements, calcium antacids and dairy (calcium carbonate, milk): Milk cut iron absorption from bisglycinate from 46.3% to 11.1% (Olivares 1997), and 300–600 mg calcium cut nonheme-iron (plant and supplement iron) absorption by 50–60% (Hallberg 1991), lowering repletion. Separating by 2 hours avoids it.
- Tea and espresso coffee: Halved iron absorption from bisglycinate (Layrisse 2000), lowering repletion. Separating by 1–2 hours avoids it.
- Green tea extract: Added to a meal, it cut nonheme-iron absorption from 12.1% to 8.9% (Samman 2001), lowering repletion. Separating doses by 2 hours avoids it.
- Other iron supplements and iron-containing multivitamins (ferrous sulfate, ferrous fumarate): Bisglycinate competes with ferrous sulfate for absorption (Pizarro 2002); combined doses raise overload and side-effect risk, avoided within the 45 mg/day upper limit (Institute of Medicine iron reference intakes), a revenue-neutral panel.
- Vitamin C: Ascorbic acid raised iron absorption from bisglycinate given in milk from 11.1% to 15.4% (Olivares 1997), but no clinical interaction was found: adding 200 mg vitamin C to oral iron did not improve hemoglobin recovery or ferritin (Li 2020).
- Intravenous iron: Adding 60 mg oral bisglycinate after intravenous iron sucrose raised hemoglobin only 0.4 g/dL more, with added side effects (Yefet 2021).
Theoretical interactions (inferred from mechanism, not studied in humans):
- Testosterone therapy (testosterone cypionate, enanthate): Inferred from additive stimulation of red cell production, as testosterone suppresses hepcidin; consequence is a higher hematocrit (red cell fraction of blood) and increased blood viscosity (thickness). Hematocrit monitoring detects it.
- Iron-binding polyphenol supplements (curcumin, quercetin): Inferred from polyphenol chelation of iron in the gut; consequence is reduced iron absorption. Separating doses by 2 hours avoids it.
Populations who should avoid Ferrous Bisglycinate:
- Hereditary hemochromatosis or iron overload: Including transferrin saturation above 45% with ferritin above 200 µg/L (premenopausal women), or above 50% with ferritin above 300 µg/L (men, postmenopausal women); EASL advises avoiding iron supplements (EASL 2022), a position from which its hepatologist members derive no revenue.
- Anemia not caused by iron deficiency (thalassemia trait, anemia of chronic inflammation) with normal or high ferritin: Inferred from the absence of a deficit to correct and the accumulation mechanism; no human data.
- Peptic ulcer or inflammatory bowel disease (regional enteritis, ulcerative colitis): Listed as contraindications to oral iron in the AHFS oral iron monograph (American Hospital Formulary Service), whose pharmacist publishers earn no revenue from them; inferred from gut-lining irritation by unabsorbed iron, no controlled human data.
- Households with children under six, unless products are stored out of reach: Accidental overdose is a leading cause of fatal childhood poisoning (21 CFR 101.17).
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Testing before supplementing: Checking ferritin, transferrin saturation and blood count first, and supplementing only with documented deficiency, prevents iron accumulation in replete users and hemochromatosis carriers.
- Investigating the cause: Gastrointestinal evaluation of men and postmenopausal women with new iron-deficiency anemia, as gastroenterologist-authored guidance recommends (Snook 2021), prevents a missed bleeding cancer; its authors’ specialty performs these endoscopies.
- Lowest effective dose: Protocols use 25 mg elemental iron daily for prevention (Milman 2014) and 60 mg for repletion (Karregat 2025), limiting gastrointestinal side effects and overload.
- Alternate-day dosing for intolerance: Switching to every other day reduces gut exposure while preserving efficacy (Karregat 2025), mitigating nausea and constipation.
- Taking with a small meal if nauseated: At some cost in absorption, this reduces nausea and abdominal pain.
- Stopping at overload thresholds: Stopping when transferrin saturation exceeds 45% with ferritin over 200 µg/L (premenopausal women), or 50% with ferritin over 300 µg/L (men, postmenopausal women) (EASL 2022, revenue-neutral for members), prevents overload.
- Child-resistant packaging and storage: Unit-dose (blister) packaging, which cut U.S. childhood iron-poisoning deaths after it became mandatory (Tenenbein 2005), and storage out of children’s reach prevent fatal childhood poisoning.
- Separating interacting medications: Spacing levothyroxine by 4 hours and fluoroquinolones by 2–6 hours prevents loss of drug effect.
Therapeutic Protocol
Doses below are cited to their source; other parameters without a citation (timing, cycling, titration steps) reflect common practice.
- Repletion dose: 60 mg elemental iron daily for 56 days most effectively cleared deficiency in donors (Karregat 2025); GlaxoSmithKline’s trial used 60 mg once daily (with folic acid, vitamin B12 and zinc) for 8 weeks in anemic women (NCT01160198).
- Prevention dose: 25 mg daily appeared adequate to prevent iron-deficiency anemia in more than 95% of pregnant Danish women (Milman 2014); 18 mg was inferior to 60 mg ferrous sulfate (Fischer 2023).
- Competing approaches: British gastroenterology guidance, a stance earning its members no revenue, puts iron salts first (Snook 2021); a Dutch trial protocol reports Danish blood-bank use of bisglycinate for intolerant donors (Karregat 2022); intravenous iron serves malabsorption.
- Alternate-day dosing: Popularized by the ETH Zurich group of Zimmermann, alternate-day ferrous sulfate raised fractional absorption (share of the dose absorbed) from 16.3% to 21.8% (Stoffel 2017); FORTE’s alternate-day bisglycinate arms nearly matched daily dosing (Karregat 2025).
- Single versus split doses: Trials favor a single daily dose: split dosing raised hepcidin without more absorbed iron (Moretti 2015), and 60 mg twice daily gave no extra hemoglobin (NCT01160198).
- Time of day: Morning, on an empty stomach, 30–60 minutes before breakfast and away from coffee, tea and calcium, matching the morning fasting doses used in absorption trials (Stoffel 2017).
- Half-life: No meaningful plasma half-life; serum iron peaks within hours, and hepcidin stays raised about 24 hours after doses of 60 mg or more (Moretti 2015), supporting once-daily or alternate-day spacing.
- Genetic polymorphisms: TMPRSS6 variants predict poor oral response, favoring intravenous iron (Heeney 2014); in HFE C282Y homozygotes, supplementation is typically reserved for confirmed deficiency.
- Sex differences: Daily needs are 18 mg for menstruating women versus 8 mg for men and postmenopausal women (Institute of Medicine iron reference intakes), a revenue-neutral panel; no trial reports a sex-specific bisglycinate dose response.
- Age: Older adults responded to 14–28 mg daily (Ferrari 2012); new deficiency after midlife often has an underlying cause, per endoscopy-performing gastroenterologists (Snook 2021).
- Baseline biomarkers: Lower ferritin predicts greater absorption (Bovell-Benjamin 2000), so dose and duration scale with the deficit; with ferritin above 100 µg/L, little benefit is expected.
- Pre-existing conditions: After gastrectomy, ferrous sulfate worked better (Mimura 2008); in chronic kidney disease, a low-dose bisglycinate tablet with vitamin C and folic acid maintained hemoglobin in an open-label study with a manufacturer co-author (Hsu 2022).
Discontinuation & Cycling
- Short-term use: Supplementation is typically a course, not lifelong: protocols continue about 3 months after hemoglobin normalizes to refill stores and end once ferritin is adequate.
- Ongoing losses: Maintenance at the lowest effective dose suits regular blood donors, heavy menstrual bleeding or plant-based diets, guided by ferritin rather than calendar.
- Withdrawal effects: None known; iron is a nutrient without dependence or rebound.
- Tapering: Not required; stopping abruptly carries no known risk.
- Cycling: Not needed for efficacy; alternate-day dosing is a dosing schedule, not cycling, and works by letting hepcidin fall between doses.
Sourcing and Quality
- Branded ingredient: Ferrochel is the original branded ferrous bisglycinate chelate from Albion (Balchem), the form used in many trials; labels naming it distinguish a chelate from blends of iron salt and glycine.
- Elemental iron on the label: Ferrous bisglycinate is roughly 20% iron by weight; products stating elemental iron per capsule, not compound weight, avoid dosing errors.
- Third-party testing: USP (United States Pharmacopeia) Verified or NSF Certified seals, or ConsumerLab testing, confirm stated iron content and absence of lead and other contaminants.
- Reputable brands: Widely available bisglycinate products include Thorne Iron Bisglycinate, Pure Encapsulations and NOW Foods; ConsumerLab’s iron supplements review compares tested products.
- Formulation: Single-ingredient products allow dose control; adding vitamin C gave no extra hemoglobin or ferritin gain in a randomized trial (Li 2020).
- Packaging: Child-resistant or blister packaging reduces poisoning risk in homes with young children.
Practical Considerations
- Time to effect: Hemoglobin rose about 1.2 g/dL by week 4 and 2.6 g/dL by week 8 on a 60 mg multi-ingredient tablet (within-group change) (NCT01160198); fatigue improvement was measured at 12 weeks (Vaucher 2012); ferritin recovers more slowly.
- Pitfall – supplementing blind: Taking iron without testing risks accumulation in replete users and hides the cause of genuine deficiency.
- Pitfall – label confusion: Mistaking compound weight for elemental iron causes underdosing; combining several iron-containing products causes overdosing.
- Pitfall – absorption blockers: Taking iron with coffee, tea, calcium or acid-suppressing medications, or splitting doses, reduces absorption.
- Pitfall – misreading ferritin: Inflammation raises ferritin, masking deficiency; pairing with CRP (C-reactive protein, an inflammation marker) avoids this.
- Regulatory status: Sold as a dietary supplement in the U.S.; FDA raised no questions about its use in fortified foods (FDA GRN 19). Iron-containing supplements in tablet or capsule form must carry a poisoning warning (21 CFR 101.17).
- Cost and payer bias: It costs more than ferrous sulfate but remains inexpensive. India’s national anemia program uses ferrous sulfate as standard care (Joshi 2026); payers favoring cheaper salts is a structural bias in guidelines, mirroring manufacturer funding of chelate trials.
Interaction with Foundational Habits
- Sleep: Indirect, potentiating where deficiency drives restless legs: iron eased restless legs symptoms but did not improve measured sleep quality (Trotti 2019). No direct effect on sleep architecture; morning dosing avoids evening gastrointestinal discomfort.
- Nutrition: Direct interaction: tea and espresso halve absorption from bisglycinate (Layrisse 2000) and milk cuts it sharply (Olivares 1997); bisglycinate is less affected by phytates than salts. Plant-based diets supply only non-heme iron (the less absorbable plant form) and raise needs; red meat supplies heme iron (the well-absorbed form bound in blood and muscle proteins).
- Exercise: Potentiating in deficient users: iron improved aerobic capacity (Pasricha 2014). Endurance training increases iron losses, and hepcidin rises for hours after hard sessions, so dosing on the morning before training or on rest days is common.
- Stress management: No direct interaction: iron did not change depression or anxiety scores (Vaucher 2012). Indirectly, correcting deficiency may lessen fatigue that undermines stress resilience; chronic inflammation from stress raises hepcidin.
Monitoring Protocol & Defining Success
Before starting, baseline testing establishes whether iron deficiency exists and rules out overload: a complete blood count with hemoglobin, ferritin with CRP, and transferrin saturation from a morning sample. Men and postmenopausal women with confirmed deficiency are also evaluated for the cause, and people on levothyroxine have a thyroid baseline. Anyone with transferrin saturation above 45% is checked for hemochromatosis before taking iron.
Ongoing monitoring follows a cadence of repeat testing at 4 weeks to confirm a hemoglobin rise of about 1 g/dL, then at 8–12 weeks, then every 6–12 months for maintenance users. Success is defined as normal hemoglobin, ferritin within the target range and improvement in fatigue or exercise tolerance. Failure to respond by 4 weeks prompts review of adherence, absorption blockers and blood loss.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Ferritin | Above 45 µg/L to exclude deficiency (AGA guideline cutoff); below 200 µg/L (premenopausal women) or 300 µg/L (men, postmenopausal women) per EASL overload thresholds | Marker the intervention is expected to change; also a safety check (stop if above the upper threshold) | AGA = American Gastroenterological Association, whose members perform the endoscopies its guideline recommends (Ko 2020); EASL 2022, whose hepatologist members derive no revenue from these thresholds. Conventional reference range roughly 15–150 µg/L (women) and 30–400 µg/L (men), laboratory-dependent. Pair with CRP; inflammation falsely raises ferritin. No fasting needed |
| Transferrin saturation | Below 45% (premenopausal women) or 50% (men, postmenopausal women) (EASL overload thresholds) | Safety check: above the threshold with raised ferritin stops use pending evaluation | EASL 2022, whose hepatologist members derive no revenue from these thresholds. Conventional reference range 20–50%. Draw in the morning after fasting and at least 24 hours after the last iron dose, as serum iron varies through the day |
| Hemoglobin | 13.5–17.5 g/dL (men); 12.0–15.5 g/dL (women) (standard reference range) | Marker the intervention is expected to change | Part of the complete blood count; pair with MCV (mean corpuscular volume, red cell size), which normalizes as deficiency resolves |
| TSH (levothyroxine users only) | 0.4–4.0 mU/L (standard reference range) | Safety check: a rise signals the iron–levothyroxine interaction | Recheck 6–8 weeks after starting iron; rising TSH prompts wider dose separation (Campbell 1992) |
Qualitative markers:
- Energy and fatigue: Daytime tiredness and mental stamina, the most commonly reported change.
- Exercise tolerance: Breathlessness, heart rate and perceived effort at familiar workloads.
- Restless legs: Evening leg discomfort and urge to move.
- Gastrointestinal tolerance: Nausea, constipation, abdominal pain; dark stools are expected and harmless.
- Other deficiency signs: Cold intolerance, brittle nails, hair shedding and cravings for ice.
Emerging Research
- EASE-Iron pregnancy trial: A University of British Columbia trial of 24 mg bisglycinate versus ferrous fumarate in 172 pregnant participants; primary endpoint maternal ferritin, recruiting, completion expected January 2027 (NCT06014983). A positive result would support an equal-dose advantage; a null result would favor the view that tolerability gains reflect lower doses.
- Albion tolerability trial: A manufacturer-sponsored phase 2 comparison of Ferrochel, iron salts and placebo for gastrointestinal tolerability in 108 participants; completion was due in 2014, status unknown, no results posted (NCT02128971). Posted results could settle the equal-dose tolerability question.
- Re-analysis after retractions: The pregnancy meta-analysis (Fischer 2023) pooled two since-retracted trials; re-pooling without them could weaken the hemoglobin and tolerability advantages.
- Long-term safety in replete adults: Genetic evidence that higher iron shortens lifespan (Daghlas 2021) calls for trials of supplementation in older iron-replete adults, which could weaken the longevity case.
- Microbiome effects: Enterobacteriaceae increases with bisglycinate (Finlayson-Trick 2023) need replication with clinical endpoints, which could strengthen or weaken safety claims.
- Absorption comparisons: A newer glycoprotein-matrix iron showed only a trend toward better absorption than bisglycinate (p = 0.07, the probability of such a result by chance, above the 0.05 cutoff) in a small crossover trial by authors paid by its maker, Ashland (Secrest 2025); larger trials could challenge bisglycinate’s absorption lead.
Conclusion
Ferrous bisglycinate is a form of supplemental iron bound to the amino acid glycine. For people who are truly low in iron, the evidence that it corrects deficiency and anemia is strong and comes from several independent research groups, including studies in blood donors, pregnant women and older adults. Its best-supported advantage over standard iron supplements is that it causes fewer stomach complaints at the lower doses it allows, although whether it is gentler at equal doses remains uncertain. Benefits for fatigue, attention, exercise capacity and restless legs are plausible for deficient users but rest on studies of other iron forms.
For people whose iron levels are already adequate, the picture changes. There is no evidence that extra iron improves health or lifespan, and genetic studies suggest that carrying more iron may shorten life. Because the body has no natural way to remove excess iron, unneeded use can lead to buildup, a particular concern for people carrying the common inherited iron-overload gene. Self-treating without finding the cause of a deficiency can also hide serious bleeding.
The evidence base is mixed in quality. Several trials were funded or co-written by the main manufacturer or supplement companies, gut-specialist guidance comes from doctors paid for the examinations it urges, and insurers favor cheaper standard iron supplements. Two trials that favored this form have been retracted, which weakens some summaries that combined many studies. Overall, ferrous bisglycinate is a well-tolerated way to fix a measured iron shortfall rather than a general longevity supplement.